Denise Beck

ORCID: 0000-0002-2730-6988 · 4 papers in corpus
article 2022
Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
British journal of clinical pharmacology ·doi:10.1111/bcp.15440

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

2021
Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women.
Clinical and translational science ·doi:10.1111/cts.13006

Decline of bone mineral density (BMD) during menopause is related to increased risk of fractures in postmenopausal women, however, this relationship in premenopausal women has not been established. To quantify this relationship, real-world …

article 2021
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
Clinical pharmacokinetics ·doi:10.1007/s40262-021-01096-w

BACKGROUND AND OBJECTIVES: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix…

article 2020
Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12560

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population expos…